The Conversation (0)
Optimi Health (CSE:OPTI,OTC:OPTHF,FRA:8BN) is focused on becoming the leading global supplier of GMP-grade psilocybin and functional mushrooms for health and wellness markets. Capitalizing on the projected 6.41 percent market growth by 2026 for the psychedelic mushroom market, the company is anticipating the opening of its specially designed facility for GMP-grade psilocybin cultivation.
The facility is already licensed by Health Canada for psilocybin manufacturing and has the capacity to produce 2,000 kilograms per month. Optimi Health’s cultivation process has a six-week growth cycle while maintaining the standards and quality of GMP guidelines.
Company Highlights
- Optimi Health aims to become a global leader in GMP-certified psilocybin and functional mushroom products to cater to the emerging psychedelic segment of the wellness industry.
- Three revenue streams are in the works to fully capitalize on the diverse needs of the growing market: Optimi Labs, Optimi Farms and Optimi Products. Optimi Products is already generating revenue, while Optimi Farms is slated to become the primary revenue driver.
This Optimi Health profile is part of a paid investor education campaign.*
OPTI:CC
